Clinical development of histone deacetylase inhibitors as anticancer agents

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 495-528

  Drummond, Daryl C ^a   Noble, Charles O ^b,c   Kirpotin, Dmitri B ^a   Guo, Zexiong ^b   Scott, Gary K ^d   Benz, Christopher C ^d  

^a Hermes Biosciences Inc   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

HDAC inhibitors; Hydroxamic acids; Targeting chromatin structure and epigenetic mechanisms; Transcription regulation

Indexed keywords

4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 7 [4 (4 CYANOPHENYL)PHENOXY]HEPTANOHYDROXAMIC ACID; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PIVALOYLOXYMETHYL BUTYRATE; TRANSCRIPTION FACTOR; TRAPOXIN; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACYLATION; ANTINEOPLASTIC ACTIVITY; BIOAVAILABILITY; CANCER GROWTH; CHROMATIN STRUCTURE; DNA PACKAGING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HYDROGEN BOND; MEDIATOR RELEASE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASES; HUMANS; PROTEASE INHIBITORS;

MAMMALIA;

EID: 13844309711     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.095825     Document Type: Review

References (182)

1. Cress WD, Seto E. 2000. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184:1-16
2. Glaser KB, Staver MJ, Waring JF, Slender J, Ulrich RG, Davidsen SK. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2:151-63
3. Van Lint C, Emiliani S, Verdin E. 1996. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5:245-53
4. Turner BM. 2002. Cellular memory and the histone code. Cell 111:285-91
5. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45
6. Sterner DE, Berger SL. 2000. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol Rev. 64:435-59
7. Jenuwein T. 2001. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 11:266-73
8. Lachner M, Jenuwein T. 2002. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14:286-98
9. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, et al. 2003. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113:507-17
10. Jason LJ, Moore SC, Lewis JD, Lindsey G, Ausio J. 2002. Histone ubiquitination: a tagging tail unfolds? Bioessays 24:166-74
11. Nathan D, Sterner DE, Berger SL. 2003. Histone modifications: now summoning sumoylation. Proc. Natl. Acad. Sci. USA 100:13118-20
12. Geiman TM, Robertson KD. 2002. Chromatin remodeling, histone modifications, and DNA methylation - how does it all fit together? J. Cell Biochem. 87:117-25
13. Nephew KP, Huang TH. 2003. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 190:125-33
14. Claus R, Lubbert M. 2003. Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489-96
15. Czermin B, Imhof A. 2003. The sounds of silence-histone deacetylation meets histone methylation. Genetica 117:159-64
16. Daujat S, Bauer UM, Shah V, Turner B, Berger S, Kouzarides T. 2002. Crosstalk between CARM1 methylation and CBP acetylation on histone H3. Curr. Biol. 12:2090-97
17. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293:1074-80
18. Beisel C, Imhof A, Greene J, Kremmer E, Sauer F. 2002. Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature 419:857-62
19. Imhof A, Becker PB. 2001. Modifications of the histone N-terminal domains. Evidence for an "epigenetic code"? Mol. Biotechnol. 17:1-13
20. Jacobs SA, Taverna SD, Zhang Y, Briggs SD, Li J, et al. 2001. Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. EMBO J. 20:5232-41
21. Hassan AH, Prochasson P, Neely KE, Galasinski SC, Chandy M, et al. 2002. Function and selectivity of bromodomains in anchoring chromatin-modifying complexes to promoter nucleosomes. Cell 111:369-79
22. Agalioti T, Chen G, Thanos D. 2002. Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381-92
23. Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, et al. 2002. Active genes are tri-methylated at K4 of histone H3. Nature 419:407-11
24. Zhang X, Yang Z, Khan SI, Horton JR, Tamaru H, et al. 2003. Structural basis for the product specificity of histone lysine methyltransferases. Mol. Cell. 12:177-85
25. Imhof A, Yang XJ, Ogryzko W, Nakatani Y, Wolffe AP, Ge H. 1997. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7:689-92
26. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, et al. 2000. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275:20436-43
27. Fu M, Rao M, Wang C, Sakamaki T, Wang J, et al. 2003. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell Biol. 23:8563-75
28. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, et al. 2001. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276:18375-83
29. Yamagata T, Mitani K, Oda H, Suzuki T, Honda H, et al. 2000. Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J. 19:4676-87
30. Boyes J, Byfield P, Nakatani Y, Ogryzko V. 1998. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594-98
31. Herrera JE, Sakaguchi K, Bergel M, Trieschmann L, Nakatani Y, Bustin M. 1999. Specific acetylation of chromosomal protein HMG-17 by PCAF alters its interaction with nucleosomes. Mol. Cell Biol. 19:3466-73
32. Imai S, Armstrong CM, Kaeberlein M, Guarente L. 2000. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795-800
33. Finnin MS, Donigian JR, Pavletich NP. 2001. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol. 8:621-25
34. Kao HY, Verdel A, Tsai CC, Simon C, Juguilon H, Khochbin S. 2001. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276:47496-507
35. Wang AH, Yang XJ. 2001. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol. Cell Biol. 21:5992-6005
36. Gray SG, Ekstrom TJ. 2001. The human histone deacetylase family. Exp. Cell Res. 262:75-83
37. Guardiola AR, Yao TP. 2002. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem. 277:3350-56
38. Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, et al. 2000. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr. Biol. 10:747-49
39. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. 2003. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370:737-49
40. Grozinger CM, Hassig CA, Schreiber SL. 1999. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. USA 96:4868-73
41. Petrie K, Guidez F, Howell L, Healy L, Waxman S, et al. 2003. The histone deacetylase 9 gene encodes multiple protein isoforms. J. Biol. Chem. 278:16059-72
42. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, et al. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307:720-28
43. Jung M. 2001. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8:1505-11
44. Miller TA, Witter DJ, Belvedere S. 2003. Histone deacetylase inhibitors. J. Med. Chem. 46:5097-116
45. Meinke PT, Liberator P. 2001. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 8:211-35
46. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, et al. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-93
47. Breslow R, Belvedere S, Gershell L. 2000. Development of cytodifferentiating agents for cancer chemotherapy. Helv. Chim. Acta 83:1685-92
48. Woo SH, Frechette S, Abou Khalil E, Bouchain G, Vaisburg A, et al. 2002. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem. 45:2877-85
49. Yoshida M, Horinouchi S, Beppu T. 1995. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17:423-30
50. Shute RE, Dunlap B, Rich DH. 1987. Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides. J. Med. Chem. 30:71-78
51. Gore SD, Carducci MA. 2000. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Invest. Drugs 9:2923-34
52. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, et al. 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62:4916-21
53. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, et al. 2001. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 61:4459-66
54. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. 2001. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl Acad. Sci. USA 98:87-92
55. el-Beltagi HM, Martens AC, Lelieveld P, Haroun EA, Hagenbeek A. 1993. Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells-preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res. 53:3008-14
56. Suzuki T, Ando T, Tsuchiya K, Fukazawa N, Saito A, et al. 1999. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42:3001-3
57. Mai A, Massa S, Ragno R, Esposito M, Sbardella G, et al. 2002. Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J. Med. Chem. 45:1778-84
58. Ragno R, Mai A, Massa S, Cerbara I, Valente S, et al. 2004.3-(4-Aroyl-1-methyl-1H-pyrrol-2-y1)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J. Med. Chem. 47:1351-59
59. Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, et al. 2003. Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem. 68:3866-73
60. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. 2003. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10:383-96
61. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. 2003. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 100:4389-94
62. Pandolfi PP. 2001. Transcription therapy for cancer. Oncogene 20:3116-27
63. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. 2001, Histone acetylation and disease. Cell Mol. Life Sci. 58:728-36
64. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194-202
65. Rosato RR, Grant S. 2004. Histone deacetylase inhibitors in clinical development. Expert Opin. Invest. Drugs 13:21-38
66. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97:10014-19
67. Vigushin DM, Coombes RC. 2002. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13
68. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. 2004. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA 101:540-45
69. Petti MC, Fazi F, Gentile M, Diverio D, De Fabritiis P, et al. 2002. Complete remission through blast cell differentiation in PLZF/RARalpha-positive acute promyelocytic leukemia: in vitro and in vivo studies. Blood 100:1065-67
70. Han JW, Ann SH, Park SH, Wang SY, Bae GU, et al. 2000. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60:6068-74
71. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, et al. 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96:4592-97
72. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. 1999. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-7
73. Primeau M, Gagnon J, Momparler RL. 2003. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 103:177-84
74. Henderson C, Brancolini C. 2003. Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. Drug Resist. Update 6:247-56
75. Johnstone RW, Licht JD. 2003. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 4:13-18
76. Kwon SH, Ann SH, Kim YK, Bae GU, Yoon JW, et al. 2002. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem. 277:2073-80
77. Cao XX, Mohuiddin I, Ece F, McConkey DJ, Smythe WR. 2001. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell Mol. Biol. 25:562-68
78. Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, et al. 2001. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor. Pathol. 18:109-14
79. Slack JL. 1999. The biology and treatment of acute progranulocytic leukemia. Curr. Opin. Oncol. 11:9-13
80. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, et al. 2003. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 63:5126-35
81. Scott GK, Marden C, Xu F, Kirk L, Benz CC. 2002. Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. Mol. Cancer Ther. 1:385-92
82. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, et al. 2003. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2:971-84
83. Kim JS, Jeung HK, Cheong JW, Maeng H, Lee ST, et al. 2004. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br. J. Haematol. 124:166-78
84. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. 2003. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765-74
85. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, et al. 2003. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res. 63:8420-27
86. Liu LT, Chang HC, Chiang LC, Hung WC. 2003. Histone deacetylase inhibitor upregulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63:3069-72
87. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, et al. 2003. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 66:897-906
88. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, et al. 2004. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65:520-27
89. Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. 2002. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int. J. Cancer 99:292-98
90. Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, et al. 2003. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines. Int. J. Cancer 104:238-42
91. Jing Y, Xia L, Waxman S. 2002. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 100:1008-13
92. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller WH Jr. 2000. Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 96:3200-8
93. Castro-Galache MD, Ferragut JA, Barbera VM, Martin-Orozco E, Gonzalez-Ros JM, et al. 2003. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int. J. Cancer 104:579-86
94. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, et al. 2003. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63:4460-71
95. Batova A, Shao LE, Diccianni MB, Yu AL, Tanaka T, et al. 2002. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood 100:3319-24
96. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, et al. 2001. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res. 29:3006-11
97. Nakamura M, Saito H, Ebinuma H, Wakabayashi K, Saito Y, et al. 2001. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J Cell Physiol. 187:392-401
98. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, et al. 2001. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7:971-76
99. Svechnikova I, Gray SG, Kundrotiene J, Ponthan F, Kogner P, Ekstrom TJ. 2003. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int. J. Oncol. 22:579-88
100. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, et al. 2003. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett. 195:161-88
101. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, et al. 2003. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4- [[(2-hydroxyethyl)[2-(1H-indol-3-yl)eth yl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J. Med. Chem. 46:4609-24
102. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, et al. 2004. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br. J. Cancer 90:535-41
103. Kosugi H, Ito M, Yamamoto Y, Towatari M, Ueda R, et al. 2001. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn. J. Cancer Res. 92:529-36
104. Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, et al. 2001. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin. Cancer Res. 1:962-70
105. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, et al. 2000. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60:5165-70
106. Arts J, Van Emelen K, Angibaud P, Van Brandt S, Poncelet V, et al. 2003. Small molecule inhibitors of histone deacetylases (HDACs): identification of JNJ16241199, a potent oral antitumoral agent. Presented at AACR-NCI-EORTC Int. Conf. Mol. Targets Cancer Ther., Boston
107. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, et al. 2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865-68
108. Siu LL, Von Hoff DD, Rephaeli A, Izbicka E, Cerna C, et al. 1998. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. Invest. New Drugs 16:113-19
109. Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, et al. 2002. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8:2142-48
110. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, et al. 2002. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62:6108-15
111. Fournel M, Trachy-Bourget MC, Yan PT, Kalita A, Bonfils C, et al. 2002. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res. 62:4325-30
112. Volpe DA, LoRusso PM, Foster BJ, Parchment RE. 2004. In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Cancer Chemother. Pharmacol. 54(1):89-94
113. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, et al. 2002. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8:718-28
114. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, et al. 2001. Chronic oral administration of CI-994: a phase 1 study. Invest. New Drugs 19:1-11
115. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, et al. 2003. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9:3578-88
116. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, et al. 2001. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98:2865-68
117. Atadja P, Gao L, Kwon P, Trogani N, Walker H, et al. 2004. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 64:689-95
118. Drummond DC, Meyer OM, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51:691-743
119. Benz C, Scott G, Berger C, Amend C, Guo Z, et al. 2003. Liposome encapsulation of histone deacetylase inhibitor enhances in vivo activity against ErbB2-positive breast cancers. Clin. Cancer Res. 9:6259s
120. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. 2003. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63:7291-300
121. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. 2000. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res. 6:681-92
122. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. 2001. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61:1327-33
123. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, et al. 2001. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20:1860-72
124. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, et al. 2003. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene 22:6231-42
125. Almenara J, Rosato R, Grant S. 2002. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 16:1331-43
126. Keen JC, Yan L, Mack KM, Pettit C, Smith D, et al. 2003. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat. 81:177-86
127. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, et al. 2001. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61:3591-94
128. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, et al. 2003. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 63:7089-93
129. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, et al. 1999. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to antileukemia therapy. Leukemia 13:1316-24
130. Zhou DC, Kim SH, Ding W, Schultz C, Warrell RP Jr, Gallagher RE. 2002. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99:1356-63
131. Giuliano M, Lauricella M, Calvaruso G, Carabillo M, Emanuele S, et al. 1999. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res. 59:5586-95
132. Yu C, Rahmani M, Almenara J, Subler M, Krystal G, et al. 2003. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res. 63:2118-26
133. Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. 2003. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236-39
134. Rosato RR, Almenara JA, Yu C, Grant S. 2004. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol. Pharmacol. 65:571-81
135. Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, Grant S. 2002. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther. 1:253-66
136. Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JHt, et al. 2003. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway. J. Thorac. Cardiovasc. Surg. 125:1132-42
137. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, et al. 2003. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum. Mol. Genet 12:1791-800
138. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. 2001. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 61:1477-85
139. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. 2001. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int. J. Oncol. 19:181-91
140. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, et al. 2004. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 10:1813-25
141. Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR. 2004. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 127:1078-86
142. Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K. 2004. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl) amino-methyl]benzamide and m-carboxy-cinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer 110:301-8
143. Chung YL, Wang AJ, Yao LF. 2004. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 3:317-25
144. Spotswood HT, Turner BM. 2002. An increasingly complex code. J. Clin. Invest. 110:577-82
145. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606
146. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, et al. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-41
147. Tomita A, Towatari M, Tsuzuki S, Hayakawa F, Kosugi H, et al. 2000. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene 19:444-51
148. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455-58
149. Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D. 1998. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol. Cell. 2:457-67
150. Waltzer L, Bienz M. 1998. Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling. Nature 395:521-25
151. Naryzhny SN, Lee H. 2004. The post-translational modifications of proliferating cell nuclear antigen (PCNA): acetylation, not phosphorylation, plays an important role in the regulation of its function. J. Biol. Chem. 279:20194-99
152. Zhang W, Bieker JJ. 1998. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl. Acad. Sci. USA 95:9855-60
153. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. 1999. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675-86
154. Soutoglou E, Katrakili N, Talianidis I. 2000. Acetylation regulates transcription factor activity at multiple levels. Mol. Cell. 5:745-51
155. Bannister AJ, Miska EA, Gorlich D, Kouzarides T. 2000. Acetylation of importin-alpha nuclear import factors by CBP/p300. Curr. Biol. 10:467-70
156. Chen LF, Greene WC. 2003. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by B acetylation. J. Mol. Med. 81:549-57
157. Goel A, Janknecht R. 2003. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol. Cell Biol. 23:6243-54
158. Jacob AL, Lund J, Martinez P, Hedin L. 2001. Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5. J. Biol. Chem. 276:37659-64
159. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, et al. 2004. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13:627-38
160. Pelletier G, Stefanovsky VY, Faubladier M, Hirschler-Laszkiewicz I, Savard J, et al. 2000. Competitive recruitment of CBP and Rb-HDAC regulates UBF acetylation and ribosomal transcription. Mol. Cell. 6:1059-66
161. Ammanamanchi S, Freeman JW, Brattain MG. 2003. Acetylated sp3 is a transcriptional activator. J. Biol. Chem. 278:35775-80
162. Huang S, Qiu Y, Shi Y, Xu Z, Brandt SJ. 2000. P/CAF-mediated acetylation regulates the function of the basic helix-loop-helix transcription factor TAL1/SCL. EMBO J. 19:6792-803
163. Yao YL, Yang WM, Seto E. 2001. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol. Cell Biol. 21:5979-91
164. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. 2000. Regulation of E2F1 activity by acetylation. EMBO J. 19:662-71
165. Sartorelli V, Puri PL, Hamamori Y, Ogryzko V, Chung G, et al. 1999. Acetylation of MyoD directed by PCAF is necessary for the execution of the muscle program. Mol. Cell. 4:725-34
166. Park SH, Lee SR, Kim BC, Cho EA, Patel SP, et al. 2002. Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyl-transferase and deacetylase is mediated by NF-Y in human breast cancer cells. J. Biol. Chem. 277:5168-74
167. Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, et al. 2001. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res. 61:931-34
168. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, et al. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA 99:11700-5
169. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, et al. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:437-43
170. Andoh A, Shimada M, Araki Y, Fujiyama Y, Bamba T. 2002. Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells. Cancer Immunol Immunother. 50:663-72
171. Zhang XD, Gillespie SK, Borrow JM, Hersey P. 2004. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3:425-35
172. Bernhard D, Skvortsov S, Tinhofer I, Hubl H, Greil R, et al. 2001. Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts. Cell Death Differ. 8:1014-21
173. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI. 1999. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 59:2981-88
174. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, et al. 2000. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60:6890-94
175. Walker GE, Wilson EM, Powell D, Oh Y. 2001. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 142:3817-27
176. Pawel JV, Shepherd F, Gatzmeier U, Natale RB, O'Brien ME, et al. 2002. Randomized phase 2 study of the oral histone deacetylase inhibitor CI-994 plus gemcitabine (Gem) vs placebo (PBO) plus GEM in second-line nonsmall cell lung cancer (NSCLC). Am. Soc. Clin. Oncol. Annu. Meet. A1239, Orlando, Florida
177. Johnson CA, Padget K, Austin CA, Turner BM. 2001. Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis. J. Biol. Chem. 276:4539-42
178. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, et al. 2004. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64:2590-600
179. Lemaire M, Momparler LF, Farinha NJ, Bernstein M, Momparler RL. 2004. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by phenylbutyrate on L1210 leukemic cells. Leuk. Lymphoma 45:147-54
180. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, et al. 2001. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 130:265-72
181. Rosato RR, Almenara JA, Dai Y, Grant S. 2003. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:1273-84
182. Guo F, Sigua C, Tao J, Ball P, George P, et al. 2004. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res. 64:2580-89